96 results
Page 2 of 5
6-K
k61gm7gg sfwb4
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
1a2 v17lw1yrzueq8mj
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
ew3mi9tp6ap
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
azcztrih
10 May 23
Current report (foreign)
7:27am
6-K
1jav44j6 cqhc
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
jujv8to
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
t61 5jjjj
18 Apr 23
Current report (foreign)
4:13pm
6-K
9rw th7fuf0znwyr
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
2agyy2r iaqpw2d
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
8qvhcc66 0fyavlkf2
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
21c6b3q6pza
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.1
s0mdkj
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.4
668ncg3569e 80
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
az4aspcacw
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
257pg2h azridjc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
90mwys94mlp02q
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-99.1
d1q2baorcnbt4cb0qj8
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
6-K
EX-1.1
ydwa s4hnqp7ixqay
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
astwm13
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
v0inkbotm
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm